Provided is a chitosan hydrogel composition including chitosan, glycerol, and a phosphate group, wherein the chitosan is crosslinked via the glycerol, the phosphate group, or a combination thereof. The temperature at which the chitosan hydrogel composition may be induced from a liquid state into a gel state may be controlled according to the content ratio of the phosphate group and the glycerol, and since printing properties and strength are affected by the gelatin concentration, the composition may be used as an ink for 3D printing.

The present technology relates to a method of augmenting soft facial tissue in a human subject using a liquid suspension including amnion allograft. Analysis of the changes to midface volume, specifically the Ogee curve, observed in the chronological progression of photographs illustrates aesthetic improvements in both Platelet Rich Plasma (PRP) and amnion allograft treatment groups, with changes in the facial grading scale. Less patient downtime and slightly more rapid improvements were noted in the amnion group in comparison to PRP treatment participants. As a result, the amnion allograft provides advantages over the PRP procedure.

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

A method of preparing a decellularized placental membrane is provided. The method comprises removing cells from a pre-decellularized placental membrane comprising an amnion layer and a chorion layer to produce a decellularized placental membrane without separating the amnion layer from the chorion layer. The pre-decellularized placental membrane is obtained from an amniotic sac, and the decellularized placental membrane comprises the amnion layer and the chorion layer. Also provided is a decellularized placental membrane and a placenta-derived graft comprising the decellularized placental membrane. Further provided are the uses of the decellularized placental membrane or the placenta-derived graft.

A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

A multi-layer collagen-based membrane that includes a bioresorbable mesh embedded between a first decellularized natural collagen-based membrane and a second decellularized natural collagen-based membrane. The bioresorbable mesh can be formed of a synthetic polymer or demineralized laminar bone. Also provided are two methods for manufacturing a multi-layer collagen-based membrane with or without an embedded bioresorbable mesh.

A method for manufacturing a cardiac valve prosthesis is disclosed. This method comprises the following steps: a) shaping human or animal body tissue in a shaping process to give the body tissue a shape of a cardiac valve, and b) fixation and stabilization of the body tissue by a cross-linking agent, thereby preserving the shape given to the body tissue by the shaping process and thus obtaining a cardiac valve prosthesis. Furthermore, a method of implanting an autologous or allogenic cardiac valve prosthesis to an individual in need thereof is disclosed.

There is disclosed a process for treatment to avert enzymatic degradation and tissue degeneration of bovine pericardium tissue, used for making bioprosthesis for implant application, comprising the steps of collecting and harvesting raw bovine pericardial tissue; chemically cross-linking the rinsed tissue to generate fixed tissue; laser cutting said fixed tissue to produce tissue leaflet; chemically treating said tissue leaflet with AAS; chemically sterilising and storing the fixed bovine pericardium tissue to maintain the structural integrity and characteristics; and wherein all the above steps are carried out in a low-oxygen and controlled temperature environment.

This disclosure provides a tissue-engineered transcatheter vein valve and methods of making such a tissue-engineered transcatheter vein valve. Methods of making the valve include casting or molding a polymer into a tubular structure having a first end and a second end, where the first end of the tubular structure is cast or molded around a tubular support structure and where the second end of the tubular structure is cast or molded in the absence of the support structure; everting the polymer at the second end through the support structure; anchoring the second end of the tubular structure to the support structure at a first position and a second position, where the anchored first position and the anchored second position result in commissures, forming leaflets therebetween.

The present disclosure describes a treatment composition comprising a nanoparticle composition comprising nanoparticles functionalized with surface amine groups and a crosslinking composition comprising genipin. The disclosure also describes a kit comprising the treatment composition, and instructions for using the kit to crosslink the nanoparticles to a tissue graft. The treatment composition and kit can be used to crosslink nanoparticles to a tissue graft, and the resulting tissue graft can be used to replace defective tissue in a subject in need thereof.